Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Basis for abnormal desquamation and permeability barrier dysfunction in RXLI.
Elias PM, Crumrine D, Rassner U, Hachem JP, Menon GK, Man W, Choy MH, Leypoldt L, Feingold KR, Williams ML. Elias PM, et al. Among authors: leypoldt l. J Invest Dermatol. 2004 Feb;122(2):314-9. doi: 10.1046/j.1523-1747.2003.22258.x. J Invest Dermatol. 2004. PMID: 15009711 Free article. Review.
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial.
Leypoldt LB, Gavriatopoulou M, Besemer B, Salwender H, Raab MS, Nogai A, Khandanpour C, Runde V, Jauch A, Zago M, Martus P, Goldschmidt H, Bokemeyer C, Dimopoulos MA, Weisel KC. Leypoldt LB, et al. Cancers (Basel). 2023 Sep 21;15(18):4667. doi: 10.3390/cancers15184667. Cancers (Basel). 2023. PMID: 37760637 Free PMC article.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Leypoldt LB, Tichy D, Besemer B, Hänel M, Raab MS, Mann C, Munder M, Reinhardt HC, Nogai A, Görner M, Ko YD, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Požek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel KC. Leypoldt LB, et al. J Clin Oncol. 2024 Jan 1;42(1):26-37. doi: 10.1200/JCO.23.01696. Epub 2023 Sep 27. J Clin Oncol. 2024. PMID: 37753960 Free PMC article.
IFNγ and CTLA-4 Drive Hepatic CD4 T-Cell Tolerance and Protection From Autoimmunity in Mice.
Krzikalla D, Laschtowitz A, Leypoldt L, Gottwick C, Averhoff P, Weidemann S, Lohse AW, Huber S, Schramm C, Schwinge D, Herkel J, Carambia A. Krzikalla D, et al. Among authors: leypoldt l. Cell Mol Gastroenterol Hepatol. 2024;17(1):79-91. doi: 10.1016/j.jcmgh.2023.09.006. Epub 2023 Sep 19. Cell Mol Gastroenterol Hepatol. 2024. PMID: 37734595 Free PMC article.
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study.
Schönlein M, Wrage V, Ghandili S, Mellinghoff SC, Brehm TT, Leypoldt LB, Utz N, Schrader RM, Alsdorf W, Börschel N, Bußmann L, Schönrock M, Perlick D, Schön G, Verpoort K, Lütgehetmann M, Schulze Zur Wiesch J, Weisel KC, Bokemeyer C, Schafhausen P, Sinn M. Schönlein M, et al. Among authors: leypoldt lb. Cancer Cell. 2022 Jun 13;40(6):581-583. doi: 10.1016/j.ccell.2022.04.016. Epub 2022 Apr 26. Cancer Cell. 2022. PMID: 35512712 Free PMC article. No abstract available.
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma.
Ghandili S, Schönlein M, Wiessner C, Becher H, Lütgehetmann M, Brehm TT, Schulze Zur Wiesch J, Bokemeyer C, Sinn M, Weisel KC, Leypoldt LB. Ghandili S, et al. Among authors: leypoldt lb. J Clin Med. 2021 Nov 24;10(23):5499. doi: 10.3390/jcm10235499. J Clin Med. 2021. PMID: 34884200 Free PMC article.
14 results